HomeROSGQ • OTCMKTS
Rosetta Genomics Ltd
$0.00
Ene 14, 12:20:16 AM GMT-5 · USD · OTCMKTS · Disclaimer
StockSegurong nakalista sa US
Nakaraang pagsara
$0.00
Market cap
10.00 USD
Average na Volume
603.00
P/E ratio
-
Dividend yield
-
Primary exchange
OTCMKTS
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
(USD)2016Y/Y na pagbabago
Kita
2.04M-29.08%
Gastos sa pagpapatakbo
13.13M-12.28%
Net na kita
-16.23M6.41%
Net profit margin
-796.13-31.96%
Kita sa bawat share
——
EBITDA
-12.36M3.39%
Aktuwal na % ng binabayarang buwis
0.26%—
Kabuuang asset
Kabuuang sagutin
(USD)2016Y/Y na pagbabago
Cash at mga panandaliang investment
4.59M-60.45%
Kabuuang asset
11.96M-46.66%
Kabuuang sagutin
7.54M169.14%
Kabuuang equity
4.42M—
Natitirang share
1.84M—
Presyo para makapag-book
0.00—
Return on assets
-45.93%—
Return on capital
-56.75%—
Net change in cash
(USD)2016Y/Y na pagbabago
Net na kita
-16.23M6.41%
Cash mula sa mga operasyon
-10.60M37.43%
Cash mula sa pag-invest
1.05M-74.56%
Cash mula sa financing
3.26M-81.18%
Net change in cash
-6.28M-239.09%
Malayang cash flow
-2.89M77.98%
Tungkol
Rosetta Genomics Ltd. was a molecular diagnostics company with offices in Israel and the United States that uses micro-ribonucleic acid biomarkers to develop diagnostic tests designed to differentiate between various types of cancer. The company expects the first three tests based on its technology to be submitted for regulatory approval in 2008. The diagnostic tests will differentiate between squamous and non-squamous non-small cell lung cancer; differentiate between adenocarcinoma and peritoneal mesothelioma; and seek to identify the origin of tumors in patients representing cancer of unknown primary. Using a single microRNA, the highly sensitive, highly specific test for squamous and non-squamous lung cancer has passed the prevalidation phase and has been submitted for approval to the New York State Department of Health Clinical Laboratory Evaluation Program in April 2008. In April 2008, Nature Biotechnology published a study by Rosetta Genomics’ scientists whose findings demonstrate microRNAs' significant potential to act as effective biomarkers that may be applied in a diagnostic test designed to identify the primary tumor site in patients CUP. Wikipedia
Itinatag
2000
Mga Empleyado
86
Search
I-clear ang paghahanap
Isara ang paghahanap
Mga app ng Google
Pangunahing menu